Closing Bell 23th October: ASX’s Rocky Ride Continues
ASX’s tumultuous journey persists, marked by significant drops in key sectors. Amidst global conflicts, the market grapples with potential shifts in economic policies.
ASX’s tumultuous journey persists, marked by significant drops in key sectors. Amidst global conflicts, the market grapples with potential shifts in economic policies.
Amidst market uncertainties, the energy sector and gold miners emerge resilient, benefiting from rising crude futures and record AUD gold prices, respectively.
Discover key financial insights with MPC Markets Weekend Investor Newsletter. Expertly curated, it guides investors through global market trends and strategies, fostering informed investment decisions. Subscribe now.
The ASX faced a harsh decline influenced by escalating Middle East tensions and unexpected shifts in Australia’s domestic unemployment figures.
The ASX today is abuzz with Whitehaven Coal’s victorious bid for BHP’s Queensland mines, a move set to redefine industry competition and market dynamics.
A recent rally in the underlying Uranium price. We are generally bullish the energy sector and see PDN as a short term buy with a ~10% trailing stop
ASX shows adaptability, navigating through RBA’s robust monetary discussions and global uncertainties, reflecting a market responsive to multifaceted economic and geopolitical influences.
*** GENERAL AVICE ONLY***
Trade Date: 17/10/2023
Recommendation
Entry price: <1.045 Target Price: >1.95
Stop Loss: 0.81 (9% trailing)
Rationale
PPK Group’s subsidiary BNNT has announced it has significantly reduced the price of its high-quality, Australian-made boron nitride nanotubes (BNNT) following a series of production improvements that have dramatically lowered the cost of production for the multi-use super material. BNNT now starts from US$150/gram, compared to the approximately US$400/gram offered by competitors.
The unfolding geopolitical turmoil in the Middle East casts a shadow over the ASX, driving fluctuations and a downturn in technology stocks.
CSL is also very close to trial results for a heart attack drug CSL112, a key pipeline product for CSL. Base case assumptions imply a valuation of around $30/share.
China’s unchanged consumer inflation in September and declining producer prices signal potential economic challenges, amidst a property crisis and waning consumer confidence.
Amidst the Israel-Hamas conflict, oil prices waver, while the Reserve Bank of Australia contemplates a potential rate hike in its upcoming November meeting.